Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma by Nathan, Paul D. et al.
 Journal of Clinical Oncology > 
 List of Issues > 
 Volume 37, Issue 15_suppl > 
MELANOMA/SKIN CANCERS 
 Rights & Permissions 
COMPANION ARTICLES 
No companion articles 
ARTICLE CITATION 
DOI: 10.1200/JCO.2019.37.15_suppl.9507 Journal of Clinical Oncology - published 
online before print May 26, 2019 
Five-year analysis on the long-term effects 
of dabrafenib plus trametinib (D + T) in 
patients with BRAF V600–mutant 
unresectable or metastatic melanoma. 
Paul D. Nathan, Caroline Robert, Jean Jacques Grob, Daniil 
Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Eugeny 
Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor 
Bondarenko, Michael A. Davies, Antoni Ribas, Keith Flaherty, Paul 
Burgess, Monique Tan, Eduard Gasal, Dirk Schadendorf, Georgina V. 
LongMount Vernon Cancer Centre, Northwood, United Kingdom; Paris-Sud 
University, Gustave Roussy, Villejuif Cedex, France; AIX-Marseille University, 
Marseille, France; Moscow City Oncology Hospital, Moscow, Russian Federation; 
Przychodnia Lekarska KOMED, Konin, Poland; University Hospital Schleswig-
Holstein, Kiel, Germany; Petrov Research Institute of Oncology, St. Petersburg, 
Russia; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 
Padova, Italy; Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, 
Sheba Medical Center, Tel-Hashomer, and Sackler Medical School, Tel-Aviv 
University, Tel-Aviv, Israel; Department of Dermatology, University of Tübingen, 
Tübingen, Germany; Dnepropetrovsk State Medical Academy, Dnepropetrovsk, 
Ukraine; The University of Texas MD Anderson Cancer Center, Houston, TX; 
University of California, Los Angeles, Los Angeles, CA; Dana-Farber Cancer 
Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA; 
Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, 
East Hanover, NJ; Department of Dermatology, University Hospital Essen, Essen, 
Germany; Melanoma Institute Australia, The University of Sydney, and Royal North 
Shore and Mater Hospitals, Sydney, Australia 
 
 Background: First-line treatment with D+T demonstrated 
prolonged progression-free survival (PFS) and overall survival (OS) 
in patients with BRAF V600–mutant unresectable or metastatic 
melanoma. With 5 years of follow-up, we report survival and 
describe characteristics of patients in the phase 3 COMBI-d and 
COMBI-v trials with long-term benefit. Methods: Pooled 5-year 
landmark data for patients treated with D+T in the phase 3 COMBI-
d (NCT01584648) and COMBI-v (NCT01597908) trials were 
analyzed. The trials enrolled patients with previously 
untreated BRAF V600E/K–mutant unresectable or metastatic 
melanoma. Patients received D 150 mg twice daily plus T 2 mg 
once daily vs either D + placebo (COMBI-d) or vemurafenib 
(COMBI-v). The primary endpoints were PFS in COMBI-d and OS 
in COMBI-v. Results: The pooled population included 563 patients 
who received D+T (COMBI-d, n = 211; COMBI-v, n = 352). Four- 
and 5-year PFS and OS rates were similar, suggesting a 
stabilization (4- and 5-year PFS, 21% [95% CI, 17%-24%] and 19% 
[95% CI, 15%-22%, respectively]; 4- and 5-year OS, 37% [95% CI, 
33%-42%] and 34% [95% CI, 30%-38%], respectively). In patients 
with normal baseline lactate dehydrogenase (LDH) levels the 5-year 
PFS rate was 25% vs 8% in patients with elevated baseline LDH 
levels. Similarly, the 5-year OS rate was considerably higher in 
patients with normal baseline LDH levels vs those with elevated 
LDH levels at baseline (43% vs 16%). Among patients with normal 
baseline LDH levels and < 3 organ sites with metastases, the 5-
year PFS and OS rates were 31% and 55%, respectively. In 
addition, exploratory analyses will be performed to characterize 
subgroup(s) of patients most likely to experience long-term benefit. 
Of 299 patients who received subsequent anticancer therapy 
following treatment with D+T, 151 (51%) received an anti–CTLA-4 
therapy and 102 (34%) received an anti–PD-1 therapy. The safety 
profile of D+T was as previously reported, and no new safety 
signals were observed. No treatment-related deaths were 
reported. Conclusions: First-line treatment with D+T leads to 
durable long-term benefit in many patients with BRAF V600–mutant 
unresectable or metastatic melanoma. Clinical trial information: 
NCT01584648; NCT01597908. 
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